Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
08:30am, Tuesday, 23'rd Apr 2024
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA
Wave Life Sciences to Present at Upcoming Investor Conferences
08:30am, Wednesday, 27'th Mar 2024
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
05:34pm, Thursday, 14'th Mar 2024
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th
Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript
12:03pm, Wednesday, 06'th Mar 2024
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2023 Earnings Call Transcript March 6, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - P
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:30am, Wednesday, 06'th Mar 2024
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-s
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
08:30am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
05:21am, Wednesday, 28'th Feb 2024
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in
Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
08:00am, Monday, 08'th Jan 2024
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Wednesday, 03'rd Jan 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d
Penny Stocks To Buy Now? 4 To Watch Before 2024
10:11am, Tuesday, 19'th Dec 2023
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
08:30am, Friday, 15'th Dec 2023
FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observ
Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering
11:56am, Thursday, 07'th Dec 2023
Wave Life Sciences Ltd.'s stock WVE, -30.57% tumbled 31% Thursday, after the clinical-stage pharma company priced a $100 million secondary share offering at $5 a share, or a discount over its closing
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
07:00am, Thursday, 07'th Dec 2023
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
04:10pm, Wednesday, 06'th Dec 2023
CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d
